Ekhart Corine, Matic Maja, Kant Agnes, van Puijenbroek Eugène, Schaik Ron van
Netherlands Pharmacovigilance Centre Lareb, Den Bosch, The Netherlands.
Department of Clinical Chemistry, Erasmus University Medical Center, Rotterdam, The Netherlands.
Pharmacogenomics. 2017 May;18(7):613-620. doi: 10.2217/pgs-2017-0197. Epub 2017 May 4.
Genetic variants for selective serotonin reuptake inhibitor (SSRI) metabolizing enzymes have been hypothesized to be a risk factor for aggression as adverse drug effect of SSRIs. Our aim was to assess the possible involvement of these polymorphisms on aggression when using SSRIs.
MATERIALS & METHODS: A retrospective noninterventional case-control study was performed on 18 cases. The genetic profile of two main genes involved in the metabolism of SSRIs was determined, and predicted phenotype frequencies were compared with Dutch controls and literature data.
Predicted CYP2C19 and CYP2D6 phenotypes for all SSRIs analyzed together did not show a significant difference between cases and controls.
We found no supporting evidence for a significant relationship between CYP2C19 and CYP2D6 polymorphisms, and aggression in patients using SSRIs.
有假设认为，选择性5-羟色胺再摄取抑制剂（SSRI）代谢酶的基因变异是导致攻击行为的一个风险因素，这是SSRI的药物不良反应。我们的目的是评估使用SSRI时这些多态性与攻击行为之间可能存在的关联。
对18例患者进行了一项回顾性非干预性病例对照研究。确定了参与SSRI代谢的两个主要基因的基因谱，并将预测的表型频率与荷兰对照组及文献数据进行了比较。
对所有分析的SSRI而言，病例组和对照组的CYP2C19和CYP2D6预测表型均无显著差异。
我们没有发现支持CYP2C19和CYP2D6多态性与使用SSRI患者的攻击行为之间存在显著关联的证据。
